Πλοήγηση ανά Συγγραφέα "Galanis, K."

Αποτελέσματα 1-3 από 3

Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir

Papatheodoridis, G. V.; Dalekos, G. N.; Yurdaydin, C.; Buti, M.; Goulis, J.; Arends, P.; Sypsa, V.; Manolakopoulos, S.; Mangia, G.; Gatselis, N.; Keskin, O.; Savvidou, S.; Hansen, B. E.; Papaioannou, C.; Galanis, K.; Idilman, R.; Colombo, M.; Esteban, R.; Janssen, H. L. A.; Lampertico, P. (2015)

Background & Aims: The risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear. We evaluated the incidence and predictors of ...
Risk and risk factors of hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF)

Papatheodoridis, G. V.; Dalekos, G. N.; Yurdaydin, C.; Goulis, I.; Arends, P.; Buti, M.; Sypsa, V.; Manolakopoulos, S.; Mangia, G.; Gatselis, N.; Keskin, O.; Savvidou, S.; Hansen, B. E.; Papaioannou, C.; Galanis, K.; Idilman, R.; Colombo, M.; Esteban, R.; Janssen, H. L.; Lampertico, P. (2013)
Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF)

Papatheodoridis, G. V.; Dalekos, G. N.; Sypsa, V.; Yurdaydin, C.; Buti, M.; Goulis, I.; Chi, H.; Manolakopoulos, S.; Mangia, G.; Gatselis, N.; Keskin, O.; Savvidou, S.; Hansen, B. E.; Vlachogiannakos, J.; Galanis, K.; Idilman, R.; Colombo, M.; Esteban, R.; Janssen, H. L.; Lampertico, P. (2014)

Πλοήγηση ανά Συγγραφέα "Galanis, K."

Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir ﻿

Risk and risk factors of hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF) ﻿

Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF) ﻿

Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir

Risk and risk factors of hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF)

Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF)